Showing papers in "American Heart Journal in 2011"

TL;DR: If positive, CANTOS would confirm the inflammatory hypothesis of atherothrombosis and provide a novel cytokine-based therapy for the secondary prevention of cardiovascular disease and new-onset diabetes.

TL;DR: In this paper, a meta-analysis of randomized controlled trials (RCTs) was conducted to estimate the effect of exercise-based cardiac rehabilitation (CR) on cardiovascular outcomes and examine the impact of CR program characteristics on the magnitude of CR benefits.

TL;DR: Results of a recent think-tank meeting in which various stakeholder groups representing key experts from consumers, community health providers, the academic community, decision-making government officials, and industry scientists met to evaluate the current status of medication adherence and provide recommendations for improving outcomes are provided.

TL;DR: The TOPCAT trial is designed to assess definitively the role of spironolactone in the management of HF-PEF, and key secondary end points include quality of life, nonfatal cardiovascular events, and new-onset atrial fibrillation.

TL;DR: Despite weight gain, smoking cessation improved HDL-C, total HDL, and large HDL particles, especially in women, and increases in HDL may mediate part of the reduced cardiovascular disease risk observed after smoking cessation.

TL;DR: A substantial number of HF deaths in this country could potentially be prevented by optimal implementation of evidence-based therapies, and the importance of performance improvement efforts to translate evidence- based therapy to routine clinical practice so as to reduce contemporary HF mortality is underscored.

TL;DR: ABMMNC therapy is safe and improves symptoms, quality of life, and possibly perfusion in patients with chronic HF.

TL;DR: This meta-analysis provides further evidence that oral L-arginine supplementation significantly lowers both systolic and diastolic BP.

TL;DR: Microvascular function improves with ACE-I therapy in women with signs and symptoms of ischemia without obstructive CAD, and this improvement is associated with reduction in angina.

TL;DR: Whether treating residual dyslipidemia with niacin further reduces cardiovascular events in patients with CV disease on a statin at target levels of low-density lipoprotein cholesterol is determined.

TL;DR: The CKD-EPI equation provides more accurate risk stratification than the MDRD Study equation in patients at high risk for CV disease, including identification of increased risk at mildly decreased eGFR.

TL;DR: In this paper, Cardiac contractility modulation (CCM) was used to deliver nonexcitatory electrical signals to the heart during the absolute refractory period intended to improve contraction.

TL;DR: The ACTION Registry-GWTG™ in-hospital mortality model and risk score represent simple, accurate risk adjustment tools for contemporary patients with acute MI.

TL;DR: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation will provide insights into "real-world" treatment including rate and rhythm control, stroke prevention, transitions to new therapies, and clinical and patient-centered outcomes among patients with AF in community practice settings.

TL;DR: A meta-analysis of randomized controlled trials comparing strategies of more versus less intensive glucose-lowering did not reduce the occurrence of HF events, and intensive glycemic control with thiazolidinediones increased the risk of HF.

TL;DR: Improved perfusion and infarct size reduction correlated with the quantity and mobility of the infused CD34(+) cells and was associated with a significant improvement in perfusion that may limit deterioration in cardiac function.

TL;DR: Troponin T measured with a newly developed hsTnT provides better diagnostic and prognostic information and, therefore, should be implemented as a standard test in clinical routine.

TL;DR: In this paper, the authors examined the incidence, predictors, and prognostic implications of acute kidney injury after transcatheter aortic valve implantation (TAVI) and found that one fifth of patients developed AKI after TAVI and that AKI was associated with increased in-hospital mortality.

TL;DR: Days alive and out of hospital, especially percent DAOH, provide a valuable tool for summarizing the overall absolute treatment effect on mortality and morbidity and can provide a useful alternative perspective on the effects of treatment in future HF trials.

TL;DR: The TAC-HFT study is a phase I/II randomized, double-blind, placebo-controlled trial designed to address several of these questions, including the optimal cell type, delivery technique, and population in stem cell-based therapies for cardiomyopathy.

TL;DR: Alogliptin, a dipeptidyl peptidase 4 inhibitor, is under development for the treatment of type 2 diabetes mellitus alone or in combination with other antidiabetic therapies.

TL;DR: In this article, the authors evaluated the safety and efficacy of LRA compared with RRA for coronary procedures and found that LRA was associated with significantly lower fluoroscopy time (149 seconds, interquartile range [IQR] 95-270 seconds).

TL;DR: A heart team-based selection of devices and access site among patients undergoing TAVI resulted in high device and procedural success and transapical access emerged as a risk factor for the Valve Academic Research Consortium-combined safety end point.

TL;DR: Elevated PTH is associated with a greater prevalence and incidence of CV risk factors and predicts a greater likelihood of prevalent and incident disease, including mortality, and persists when adjusted for 25(OH)D, renal function, and standard risk factors.

TL;DR: This review focuses on the pathophysiology and various etiologies that lead to thoracic aortic aneurysm along with the diagnostic modalities and management of asymptomatic patients with thoraco-aortic disease.

TL;DR: Idebenone did not decrease LV hypertrophy or improve cardiac function in subjects with FRDA and the present study does not provide evidence of benefit in this cohort over a 6-month treatment period.

TL;DR: In this paper, a meta-analysis of randomized trials of aspirin versus placebo/control to assess the effect of aspirin on major cardiovascular events (MCEs) (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), individual components of the MCE, stroke subtype, all-cause mortality, and major bleeding was performed.

TL;DR: Cardiac comorbidities (low-gradient aortic stenosis, tricuspidal valve regurgitation) are associated with all-cause mortality, whereas mitral valve Regurgitation is a risk factor for poor treatment response after TAVI.

TL;DR: In this paper, a double-blind, randomized, controlled pilot trial, 43 patients with severe, nonischemic heart failure received 1 g/d n3-polyunsaturated fatty acids (n3-PUFAs) or placebo for 3 months, and showed a dose-dependent increase in left ventricular ejection fraction (LVEF), flow-mediated vasodilation, plasma high-sensitive interleukin 6 and high sensitive tumor necrosis factor α.

TL;DR: Low fitness and central obesity were independently and cumulatively associated with increased mortality in coronary artery disease patients attending cardiac rehabilitation and the association of BMI with mortality is complex and altered by fitness levels.